LONG BEACH, Calif. — In this video from the American Society of Retina Specialists annual meeting, Arshad M. Khanani, MD, MA, FASRS, presents 3.5-year results from the TRUCKEE study.
The study investigated the efficacy, safety and durability of Vabysmo (faricimab-svoa, Genentech) for neovascular age-related macular degeneration in a real-world setting.
“Faricimab continues to be well tolerated in patients with neovascular AMD,” Khanani, of Sierra Eye Associates in Reno, Nevada, told Healio. “We are seeing rapid improvement in anatomy in previously treated as well as